logo
Book a meeting
PharmAkea Therapeutics

Pharm Akea Therapeutics

Pharmaceuticals, El Camino Real, San Diego, , 92130, California, 12780, United States, 11-50 Employees

pharmakea.com

  • LinkedIn

Who is PHARMAKEA THERAPEUTICS

PharmAkea is a privately held San Diego-based clinical-stage pharmaceutical company developing novel small molecules against protein targets involved in fibroproliferative diseases. The c...

Read More

lock icon Get Full Access
map
  • 12780 El Camino Real, San Diego, California, 92130, United States Headquarters: 12780 El Camino Real, San Diego, California, 92130, United States
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Million to $5 Million

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 5122

checked-icon Does something look wrong? Fix it. | View contact records from PHARMAKEA THERAPEUTICS

PharmAkea Therapeutics Org Chart and Mapping

Employees
Kevin Holme

Kevin Holme

Independent Consultant

See Full Org Chart arrow
email-formate-icon
View Email Formats for PharmAkea Therapeutics
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding PharmAkea Therapeutics

Answer: PharmAkea Therapeutics's headquarters are located at El Camino Real, San Diego, , 92130, California, 12780, United States

Answer: PharmAkea Therapeutics's official website is https://pharmakea.com

Answer: PharmAkea Therapeutics's revenue is $1 Million to $5 Million

Answer: PharmAkea Therapeutics's SIC: 5122

Answer: PharmAkea Therapeutics has 11-50 employees

Answer: PharmAkea Therapeutics is in Pharmaceuticals

Answer: PharmAkea Therapeutics contact info: Phone number: Website: https://pharmakea.com

Answer: PharmAkea is a privately held San Diego-based clinical-stage pharmaceutical company developing novel small molecules against protein targets involved in fibroproliferative diseases. The company was funded through a collaboration with Celgene and a venture round by Bay City Capital. The companys lead program is PAT-1251, a Phase 2 ready LOXL2 inhibitor, for the treatment of fibrotic diseases and some cancers. PharmAkea spun out PAT-409, a Phase 1 ready autotaxin inhibitor, in 2019, and that program was subsequently purchased by Blade Therapeutics.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access